Literature DB >> 48066

Infectious mononucleosis: model for self-limiting lymphoproliferation.

R L Carter.   

Abstract

Evidence for the extensive lymphoproliferation which characterises infectious mononucleosis (I.M.) is summarised, and some of the mechanisms which are though to control lymphoproliferative activity in this disease are discussed. The main host responses which appear to limit lymphoproliferation in I.M. include the development of humoral antibodies against the Epstein-Barr (E.B.) virus-associated membrane antigen (present on the E.B. viral envelope and on E.B.-virus-infected cells) and cellular immune responses directed against E.B.-virus-containing lymphocytes. Recent evidence is reviewed which indicates that E.B. virus preferentially infects B lymphocytes and that these E.B.-virus-containing cells, which are altered antigenically, evoke a massive response in the host T cells which do not carry E.B. virus; in the presence of E.B.-virus-infected B cells, T cells are transformed and become cytotoxic for B cells. Some of the general implications of the predominant T-cell response in I.M. are discussed with particular relation to autoantibody formation and antigenic competition. The possible role of the distinctive heterophil antigens and antibodies in determining the self-limiting course of I.M. is briefly considered. The general status of I.M. as a self-limiting, albeit intense, lymphoproliferative disease is appraised and the tenuous relationship between I.M. and irreversible lymphoproliferative states is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48066     DOI: 10.1016/s0140-6736(75)93014-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

Review 1.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

2.  H-rosette formation in T-cell-proliferative diseases.

Authors:  P J Sheldon; E J Holborow
Journal:  Br Med J       Date:  1975-11-15

3.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

4.  Development of cell-mediated immunity to Epstein-Barr herpesvirus in infectious mononucleosis as shown by leukocyte migration inhibition.

Authors:  P K Lai; M P Alpers; E M MacKay-Scollay
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

5.  IgM and IgG antibody levels to ampicillin in patients with infectious mononucleosis.

Authors:  H McKenzie; D Parratt; R G White
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

6.  Antibody formation by human tonsil cells in vitro.

Authors:  Z Baumöhl; B Kellerhals; W Stolp; I Lefkovits
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

7.  B lymphocytopenia in infectious mononucleosis.

Authors:  C V Sumaya; R G Keightley
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

8.  Electrophoretic mobility of lymphocyte subpopulations in infectious mononucleosis.

Authors:  D C Donald; D O Ho-Yen; F Hutchinson; T M Macleod
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

9.  Relationship of in vitro immune responses to Epstein-Barr herpesvirus and severity of infectious mononucleosis.

Authors:  K Goldstein; P K Lai; M Lightfoote; A P Andrese; D Fuccillo; R J Connor; P H Levine
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

10.  Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis.

Authors:  M Jondal
Journal:  Clin Exp Immunol       Date:  1976-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.